Elastase inhibitory activity of airway α1-antitrypsin is protected by treatment with a catalytic antioxidant in a baboon model of severe bronchopulmonary dysplasia

Çagatay Karaaslan, Hiroshi Hirakawa, Ryuji Yasumatsu, Ling Yi L Chang, Richard A. Pierce, James D. Crapo, Sule Cataltepe

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Recent studies in animal models of bronchopulmonary dysplasia (BPD) suggest that antioxidant treatments may be beneficial for the disease. However, the mechanisms by which these drugs improve the course of BPD are not completely known. Alpha1-antitrypsin (α1-AT) is one of the major serine protease inhibitors in human plasma that has antielastase and antiapoptotic activities. Both activities of α1-AT are dependent on its reactive site loop (RSL), which is highly susceptible to oxidative inactivation. In this study, we investigated the elastase inhibitory activity of α1-AT in two different baboon models of BPD, the "new BPD" and the "severe BPD" models, and determined the effect of treatment with a catalytic antioxidant, Mn(III) meso-tetrakis(N-ethylpyridinium-2-yl)porphyrin (MnTE-2-PyP), on the elastase inhibitory activity of α1-AT in the severe BPD model. Our results demonstrate the presence of sufficient elastase inhibitory activity of the airway α1-AT in the new but not in the severe BPD model. Treatment of severe BPD group baboons with the catalytic antioxidant MnTE-2-PyP resulted in augmentation of the elastase inhibitory activity of α1-AT. These findings suggest that prevention of the oxidative inactivation of α1-AT may be one of the mechanisms by which antioxidant therapy improves the pulmonary outcomes in animal models of severe BPD.

Original languageEnglish
Pages (from-to)363-367
Number of pages5
JournalPediatric Research
Volume70
Issue number4
DOIs
Publication statusPublished - Oct 1 2011

Fingerprint

Bronchopulmonary Dysplasia
Papio
Pancreatic Elastase
Antioxidants
Animal Models
Serine Proteinase Inhibitors
Porphyrins
Catalytic Domain
Lung

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health

Cite this

Elastase inhibitory activity of airway α1-antitrypsin is protected by treatment with a catalytic antioxidant in a baboon model of severe bronchopulmonary dysplasia. / Karaaslan, Çagatay; Hirakawa, Hiroshi; Yasumatsu, Ryuji; Chang, Ling Yi L; Pierce, Richard A.; Crapo, James D.; Cataltepe, Sule.

In: Pediatric Research, Vol. 70, No. 4, 01.10.2011, p. 363-367.

Research output: Contribution to journalArticle

Karaaslan, Çagatay ; Hirakawa, Hiroshi ; Yasumatsu, Ryuji ; Chang, Ling Yi L ; Pierce, Richard A. ; Crapo, James D. ; Cataltepe, Sule. / Elastase inhibitory activity of airway α1-antitrypsin is protected by treatment with a catalytic antioxidant in a baboon model of severe bronchopulmonary dysplasia. In: Pediatric Research. 2011 ; Vol. 70, No. 4. pp. 363-367.
@article{217843bed4d043f9ba0701a077540d99,
title = "Elastase inhibitory activity of airway α1-antitrypsin is protected by treatment with a catalytic antioxidant in a baboon model of severe bronchopulmonary dysplasia",
abstract = "Recent studies in animal models of bronchopulmonary dysplasia (BPD) suggest that antioxidant treatments may be beneficial for the disease. However, the mechanisms by which these drugs improve the course of BPD are not completely known. Alpha1-antitrypsin (α1-AT) is one of the major serine protease inhibitors in human plasma that has antielastase and antiapoptotic activities. Both activities of α1-AT are dependent on its reactive site loop (RSL), which is highly susceptible to oxidative inactivation. In this study, we investigated the elastase inhibitory activity of α1-AT in two different baboon models of BPD, the {"}new BPD{"} and the {"}severe BPD{"} models, and determined the effect of treatment with a catalytic antioxidant, Mn(III) meso-tetrakis(N-ethylpyridinium-2-yl)porphyrin (MnTE-2-PyP), on the elastase inhibitory activity of α1-AT in the severe BPD model. Our results demonstrate the presence of sufficient elastase inhibitory activity of the airway α1-AT in the new but not in the severe BPD model. Treatment of severe BPD group baboons with the catalytic antioxidant MnTE-2-PyP resulted in augmentation of the elastase inhibitory activity of α1-AT. These findings suggest that prevention of the oxidative inactivation of α1-AT may be one of the mechanisms by which antioxidant therapy improves the pulmonary outcomes in animal models of severe BPD.",
author = "{\cC}agatay Karaaslan and Hiroshi Hirakawa and Ryuji Yasumatsu and Chang, {Ling Yi L} and Pierce, {Richard A.} and Crapo, {James D.} and Sule Cataltepe",
year = "2011",
month = "10",
day = "1",
doi = "10.1203/PDR.0b013e31822a357e",
language = "English",
volume = "70",
pages = "363--367",
journal = "Pediatric Research",
issn = "0031-3998",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Elastase inhibitory activity of airway α1-antitrypsin is protected by treatment with a catalytic antioxidant in a baboon model of severe bronchopulmonary dysplasia

AU - Karaaslan, Çagatay

AU - Hirakawa, Hiroshi

AU - Yasumatsu, Ryuji

AU - Chang, Ling Yi L

AU - Pierce, Richard A.

AU - Crapo, James D.

AU - Cataltepe, Sule

PY - 2011/10/1

Y1 - 2011/10/1

N2 - Recent studies in animal models of bronchopulmonary dysplasia (BPD) suggest that antioxidant treatments may be beneficial for the disease. However, the mechanisms by which these drugs improve the course of BPD are not completely known. Alpha1-antitrypsin (α1-AT) is one of the major serine protease inhibitors in human plasma that has antielastase and antiapoptotic activities. Both activities of α1-AT are dependent on its reactive site loop (RSL), which is highly susceptible to oxidative inactivation. In this study, we investigated the elastase inhibitory activity of α1-AT in two different baboon models of BPD, the "new BPD" and the "severe BPD" models, and determined the effect of treatment with a catalytic antioxidant, Mn(III) meso-tetrakis(N-ethylpyridinium-2-yl)porphyrin (MnTE-2-PyP), on the elastase inhibitory activity of α1-AT in the severe BPD model. Our results demonstrate the presence of sufficient elastase inhibitory activity of the airway α1-AT in the new but not in the severe BPD model. Treatment of severe BPD group baboons with the catalytic antioxidant MnTE-2-PyP resulted in augmentation of the elastase inhibitory activity of α1-AT. These findings suggest that prevention of the oxidative inactivation of α1-AT may be one of the mechanisms by which antioxidant therapy improves the pulmonary outcomes in animal models of severe BPD.

AB - Recent studies in animal models of bronchopulmonary dysplasia (BPD) suggest that antioxidant treatments may be beneficial for the disease. However, the mechanisms by which these drugs improve the course of BPD are not completely known. Alpha1-antitrypsin (α1-AT) is one of the major serine protease inhibitors in human plasma that has antielastase and antiapoptotic activities. Both activities of α1-AT are dependent on its reactive site loop (RSL), which is highly susceptible to oxidative inactivation. In this study, we investigated the elastase inhibitory activity of α1-AT in two different baboon models of BPD, the "new BPD" and the "severe BPD" models, and determined the effect of treatment with a catalytic antioxidant, Mn(III) meso-tetrakis(N-ethylpyridinium-2-yl)porphyrin (MnTE-2-PyP), on the elastase inhibitory activity of α1-AT in the severe BPD model. Our results demonstrate the presence of sufficient elastase inhibitory activity of the airway α1-AT in the new but not in the severe BPD model. Treatment of severe BPD group baboons with the catalytic antioxidant MnTE-2-PyP resulted in augmentation of the elastase inhibitory activity of α1-AT. These findings suggest that prevention of the oxidative inactivation of α1-AT may be one of the mechanisms by which antioxidant therapy improves the pulmonary outcomes in animal models of severe BPD.

UR - http://www.scopus.com/inward/record.url?scp=80052556037&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052556037&partnerID=8YFLogxK

U2 - 10.1203/PDR.0b013e31822a357e

DO - 10.1203/PDR.0b013e31822a357e

M3 - Article

VL - 70

SP - 363

EP - 367

JO - Pediatric Research

JF - Pediatric Research

SN - 0031-3998

IS - 4

ER -